Drug Trial Radar · NCT01741155
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Oct 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
34
Actual
Start
May 2013
Primary completion
Jul 2015
Study completion Jul 2015
Sponsor
- Lead sponsor
- Spectrum Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 4, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to estimate and compare the objective response rate of SPI-1620 administered in combination with docetaxel in patients with NSCLC and to determine the safety of SPI-1620 when administered in combination with docetaxel.
Conditions
- Non Small Cell Lung Cancer (NSCLC)
Interventions
SPI-1620Drug
SPI-1620 11 μg/m2 administered intravenously over one minute.
DocetaxelDrug
Docetaxel: 75 mg/m2 administered as IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate(ORR) of SPI-1620Time frame: Up to 2 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Oncology Hematology Care Inc.
Cincinnati, Ohio
Tennessee Oncology PLLC
Chattanooga, Tennessee
Tennessee Oncology
Nashville, Tennessee
The Center for Cancer and Blood Disorders
Fort Worth, Texas
Virginia Cancer Institute
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.